Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026

|
November 18, 2026
X min read
  • Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability
  • STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a)
  • Results reinforce Scribe’s approach to addressing a critical unmet need in cardiovascular care: ultra-long-acting therapies designed to sustainably and substantially lower atherogenic lipoproteins and empower patients to prevent disease before it develops
|
November 18, 2026
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky